{"classes":[{"categories":[{"measurements":[{"comment":"Due to small number of participants with an event, median and upper limit of 95% confidence interval (CI) could not be calculated.","groupId":"OG000","lowerLimit":"10.2","upperLimit":"NA","value":"NA"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"5"}],"units":"Participants"}],"description":"TTP was defined as the time interval from the date of first dose to the date of disease progression. Disease progression was defined as any 1 or more of the following: Increase of 25% or more from lowest response level in any 1 or more of the following: - serum M-component (absolute increase must be ≥0.5 g/dL), - urine M-component (absolute increase must be ≥200 mg/24 hours), bone marrow plasma cell percentage ≥10%; definite development of new bone lesions or soft tissue plasmacytomas or definite increase in the size of existing bone lesions or soft tissue plasmacytomas; and development of hypercalcemia (corrected serum calcium \\>11.5 mg/dL) that could be attributed solely to the plasma cell proliferation disorder.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received CEP-18770 Dose B IV on Days 1, 8, and 15 in each 28-day cycle. In addition, participants received a fixed dose of 25 mg oral lenalidomide on Days 1 through 21 and a fixed dose of 40 mg oral dexamethasone on Days 1, 8, 15, and 22 of each 28-day cycle.","id":"OG000","title":"CEP-18770 Dose B"}],"paramType":"MEDIAN","populationDescription":"The full analysis set included all participants who received at least 1 dose of CEP-18770 at the MTD, including participants treated at the MTD of CEP-18770 in Part 1 and who had at least 1 response assessment, or who discontinued treatment due to toxicity or death. Participants who did not have a response assessment were considered non-responders.","reportingStatus":"POSTED","timeFrame":"From the date of first dose of study drug to the date of disease progression (up to approximately 1.5 years)","title":"Time to Progression (TTP) for Participants Treated With CEP-18770 at the MTD, as Assessed Using IMWG Criteria","type":"SECONDARY","unitOfMeasure":"months"}